Form 4: Bicycle Therapeutics CEO Sells Shares for Tax Obligations

Bicycle Therapeutics CEO Kevin Lee sold ordinary shares to cover statutory tax withholding obligations related to restricted stock unit vesting, not as a discretionary sale.

Summary

• Kevin Lee, Chief Executive Officer and Director of Bicycle Therapeutics PLC (BCYC), reported the sale of ordinary shares.
• On October 2, 2025, 2,263 ordinary shares were sold at a weighted average price of $8.40 per share, with prices ranging from $8.31 to $8.45.
• On October 3, 2025, an additional 3,231 ordinary shares were sold at a weighted average price of $8.41 per share, with prices ranging from $8.40 to $8.50.
• These sales were non-discretionary, mandated by the reporting person's award agreement to satisfy minimum statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs).
• Following these transactions, Kevin Lee directly beneficially owns 475,310 ordinary shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the share sales are non-discretionary 'sell to cover' transactions for tax purposes, not indicative of management's confidence or lack thereof in the company's future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale of shares represents the number required to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units.
• This transaction is mandated by the reporting person's award agreement and does not represent a discretionary sale.

Industry Context

This Form 4 filing reports an insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The transaction is a routine 'sell to cover' for tax purposes, which typically has minimal impact on shareholder perception as it does not signal a change in management's view of the company's value. It results in a minor reduction in the CEO's direct beneficial ownership.

Key Dates

Recommendation

The reported share sales by CEO Kevin Lee are non-discretionary 'sell to cover' transactions to satisfy tax obligations related to RSU vesting. This is a routine event and does not reflect a change in the company's fundamentals or management's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Bicycle Therapeutics, BCYC, Kevin Lee, Form 4, Insider Transaction, Share Sale, CEO, Restricted Stock Units, Tax Withholding